List of Excipients in Branded Drug ILOPERIDONE

Generic Drugs Containing ILOPERIDONE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	iloperidone	0378-0630	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	iloperidone	0378-0630	CROSPOVIDONE
Mylan Pharmaceuticals Inc	iloperidone	0378-0630	HYPROMELLOSE
Mylan Pharmaceuticals Inc	iloperidone	0378-0630	LACTOSE MONOHYDRATE
Mylan Pharmaceuticals Inc	iloperidone	0378-0630	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in ILOPERIDONE?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
2	CROSPOVIDONE
2	HYPROMELLOSE
2	LACTOSE MONOHYDRATE
2	MAGNESIUM STEARATE

Iloperidone Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Iloperidone, marketed in the United States as Fanapt, has a formulation profile shaped by three commercial constraints: a required food intake of at least 350 calories, a seven-day titration schedule, and exposure variability linked to CYP2D6 metabolism. The current product is an immediate-release tablet. The strongest excipient opportunities are therefore food-effect mitigation, faster titration, flexible oral delivery, improved adherence, and differentiated modified-release products rather than simple tablet-cost reduction.

Generic competition and method-of-use patent litigation have reduced the value of an undifferentiated iloperidone tablet. A new product needs a clear clinical or regulatory distinction, such as lower food dependence, orally disintegrating delivery, pediatric suitability, reduced pill burden, or a long-acting injectable formulation.

What is the FDA regulatory status of iloperidone?

Iloperidone is an FDA-approved atypical antipsychotic indicated for the acute treatment of schizophrenia in adults. Fanapt is supplied as immediate-release tablets in 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg strengths. The label requires dose titration over seven days to reduce orthostatic hypotension risk. Administration should occur with food because a meal of at least 350 calories materially increases exposure.[1]

FDA product profile

Attribute	Iloperidone status
Active ingredient	Iloperidone
Brand	Fanapt
Original developer	Novartis
Current U.S. rights holder	Vanda Pharmaceuticals
Dosage form	Immediate-release oral tablet
Approved indication	Adult schizophrenia
Initial U.S. approval	2009
Dose range	1 mg to 12 mg twice daily, depending on regimen
Titration	Seven-day upward titration
Food requirement	At least 350 calories
Major safety issue	QT prolongation, orthostatic hypotension and metabolic effects
Metabolism	CYP2D6 and CYP3A4 pathways
FDA pathway for a copy	ANDA, subject to Orange Book certifications

The drug carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis. It is not approved for that use.[1]

What excipients are used in Fanapt tablets?

Fanapt is an immediate-release, film-coated tablet using conventional pharmaceutical excipients. The U.S. prescribing information identifies excipients including lactose monohydrate, microcrystalline cellulose, hypromellose, croscarmellose sodium, magnesium stearate and colloidal silicon dioxide. Colorants vary by tablet strength and may include iron oxides.[1]

Functional role of the current excipients

Excipient class	Likely formulation function
Lactose monohydrate	Diluent and tablet mass builder
Microcrystalline cellulose	Diluent, compressibility and compact strength
Croscarmellose sodium	Superdisintegrant
Hypromellose	Film coating and mechanical protection
Colloidal silicon dioxide	Glidant and flow aid
Magnesium stearate	Lubricant
Iron oxides	Strength identification and color coding

The current formulation is technically conventional. Its principal commercial weakness is not tablet manufacturability. It is the clinically relevant food requirement. A reformulated product that allows consistent exposure without a calorie-dependent meal could create a stronger commercial position than a formulation with only improved hardness, friability or dissolution.

What formulation problems create the largest excipient opportunities for iloperidone?

Food-effect mitigation

The FDA label requires administration with food because food increases systemic exposure. This creates a direct opportunity for excipient systems that improve drug dispersion, dissolution and absorption under fasted conditions.

Candidate approaches include:

• Amorphous solid dispersions using polymers such as hypromellose acetate succinate, hydroxypropyl methylcellulose or povidone.
• Lipid-based systems using medium-chain triglycerides, surfactants and self-emulsifying excipients.
• Co-processed carriers that improve wetting and reduce hydrophobic drug aggregation.
• Particle-size engineering combined with wetting agents.
• Granulation systems that stabilize a high-energy drug form.
• Supersaturating formulations with precipitation inhibitors.

The development target should be exposure equivalence between fed and fasted states, not merely faster dissolution in compendial media. A sponsor would need comparative food-effect studies and a robust control strategy for physical stability.

Faster titration

The seven-day titration schedule limits convenience during initiation and may delay therapeutic dosing. Excipients alone may not remove the pharmacologic basis for titration, but a formulation could support dose flexibility through:

• Low-dose multiparticulates.
• Scored tablets with validated dose uniformity.
• Oral powders or granules for precise dose escalation.
• Orally disintegrating tablets in 1 mg and 2 mg strengths.
• Unit-dose blister packaging integrated with a titration calendar.

A titration pack is a practical lifecycle product. It requires limited formulation change and can improve initiation adherence, reduce dispensing errors and support outpatient prescribing.

Oral disintegration and swallowability

Patients with schizophrenia can have poor adherence, dysphagia, cognitive impairment or limited access to water. An orally disintegrating tablet could provide a differentiated dosage form, particularly if it preserves dose accuracy across the 1 mg to 12 mg range.

Potential excipient systems include:

• Mannitol-based rapidly dissolving matrices.
• Crospovidone or croscarmellose sodium for rapid breakup.
• Low-moisture granulation systems.
• Flavoring and taste-masking agents.
• Saliva-activated porous tablets.
• Blister packaging that protects against humidity.

Taste masking is a meaningful technical issue. Iloperidone is not generally positioned as a highly palatable molecule, and a taste-masked formulation would need a demonstrated improvement in acceptability without delaying absorption.

How can excipients support long-acting iloperidone products?

A long-acting injectable could reduce daily pill burden and address adherence, but its technical and regulatory profile is substantially different from the current tablet.

Potential long-acting platforms

Platform	Commercial rationale	Main development barrier
Aqueous nanosuspension	Enables low-solubility drug delivery	Particle-size control, injection tolerability and depot release
PLGA microspheres	Established sustained-release technology	Initial burst, manufacturing complexity and residual solvent
In situ depot	Potentially extended release after injection	Local tolerability and reproducible depot formation
Lipid depot	May support prolonged release	Physical stability and injection viscosity
Crystalline suspension	Can extend release without polymer	Sterility, sedimentation and dose uniformity

An injectable would need to account for iloperidone’s QT-prolongation liability, metabolism and dose titration requirements. A long-acting formulation may have a slower reversibility profile if adverse events occur. The commercial case is strongest if the product can demonstrate reliable exposure, acceptable injection intervals and reduced relapse from nonadherence.

Excipient suppliers with sterile suspension, injectable polymer or nanoparticle capabilities may find a licensing opportunity with a generic manufacturer or specialty pharmaceutical company. The value is likely to reside in formulation know-how and manufacturing controls rather than in a commodity excipient.

What patents protect iloperidone formulations and uses?

Iloperidone’s core composition-of-matter protection has expired in the United States. Commercial patent risk has shifted toward method-of-use, pharmacogenomic and formulation claims.

Key patent categories

Patent category	Relevance to commercial strategy
Composition of matter	Core molecule protection is no longer the main barrier
Tablet formulation	Can protect specific excipient combinations or manufacturing processes
Food-effect reduction	Potential basis for a differentiated product
CYP2D6-guided dosing	Method-of-use protection affects certain generic launch strategies
Long-acting delivery	Potential new patent estate for injectable or depot products
Orally disintegrating delivery	Can support a separate dosage-form franchise
Manufacturing process	May protect solid-state control, granulation or scale-up methods

The key branded-product litigation involved Vanda’s patent covering a method of treating patients with iloperidone based on CYP2D6 metabolizer status. The Federal Circuit addressed Vanda’s infringement dispute with Teva in 2023.[2] That patent is separate from excipient protection and does not automatically block every formulation or generic product. Its practical value depends on claim scope, enforceability, remaining term and the labeling proposed by an ANDA applicant.

Current patent and Orange Book determinations require review of the FDA’s live Orange Book, issued patents and court dockets. Patent expiration dates should not be inferred from the original product approval date alone.[3]

What is the Orange Book status of Fanapt and generic iloperidone?

The Orange Book identifies approved drug products, therapeutic-equivalence information and patents submitted by reference-product sponsors. For iloperidone, the commercial analysis should separate:

1. The reference listed drug, Fanapt.
2. Approved ANDA products.
3. Listed patents and pediatric-exclusivity information.
4. Paragraph IV certifications.
5. Any 30-month stays or settlement restrictions.
6. Whether an ANDA applicant has adopted a carve-out label.

An ANDA applicant challenging a listed patent may file a Paragraph IV certification. The reference-product sponsor can then bring an infringement action, potentially triggering a 30-month stay under the Hatch-Waxman framework. A generic applicant may also certify that a patent has expired, will expire before launch or is not infringed by the proposed product.

For excipient-led products, the critical distinction is between:

• A conventional generic tablet that must address listed patents and bioequivalence.
• A 505(b)(2) product with a new dosage form, route, formulation or food-effect claim.
• A new product supported by clinical studies and an independent patent estate.

A modified-release, injectable or orally disintegrating iloperidone product may not fit cleanly within a conventional ANDA strategy. The regulatory pathway will depend on whether the product can rely on the reference drug’s safety and efficacy findings and whether the proposed differences require new clinical evidence.

How strong is the iloperidone patent estate for a new formulation?

The patent estate is stronger for new clinical functionality than for routine excipient substitution.

Higher-value patent opportunities

A formulation patent is more defensible when it claims a measurable product advantage, such as:

• Reduced fed-versus-fasted exposure variability.
• A defined pharmacokinetic profile.
• A stable amorphous form with controlled impurity growth.
• A long-acting release interval.
• Improved dose accuracy during titration.
• A clinically meaningful reduction in administration burden.
• A specific multiparticulate structure or depot architecture.

Claims limited to replacing one diluent with another are more vulnerable to obviousness challenges, especially where the substitution is routine and does not generate an unexpected result.

A stronger portfolio could combine composition claims, process claims, dissolution specifications, pharmacokinetic claims and method-of-use claims. Patent term extension may be relevant only to eligible patents covering the approved product, and a new excipient combination would generally rely on its own filing date and patent term.

Which commercial opportunities exist for iloperidone excipients?

1. Food-independent immediate-release tablets

This is the highest-value oral opportunity. A product that produces comparable exposure under fed and fasted conditions could address a clear label limitation. The commercial package would require:

• Comparative bioavailability.
• Fed and fasted pharmacokinetics.
• Dose-proportionality data.
• Solid-state stability.
• Dissolution method discrimination.
• A regulatory strategy for revised administration instructions.

2. Orally disintegrating tablets

An ODT could target adherence, dysphagia and supervised administration. The best initial strengths are likely 1 mg, 2 mg and 4 mg because those doses support titration. Commercial value would increase if the product could be supplied in a calendar blister pack.

3. Titration kits

A titration kit could combine existing strengths with packaging and patient instructions. It has lower technical risk than a novel delivery system and may be attractive to specialty pharmacies, hospitals and managed-care programs.

4. Long-acting injectable products

This is the largest potential product differentiation opportunity but also the highest-risk program. It would require sterile manufacturing, depot-release control, injection-site studies and a safety strategy for prolonged exposure.

5. Pediatric or geriatric-friendly dosage forms

Iloperidone is approved for adults, so pediatric development would require a separate clinical program. A liquid, sprinkle formulation or low-dose multiparticulate product could support a pediatric extension, but the commercial opportunity depends on clinical development and patent timing.

6. Excipient technology licensing

Suppliers can pursue licensing or co-development agreements involving:

• Spray-dried dispersion platforms.
• Lipid-based absorption systems.
• Nanocrystal technology.
• Taste-masking systems.
• PLGA or aqueous depot systems.
• Moisture-protective packaging and unit-dose delivery.

The strongest licensing proposition would include iloperidone-specific data showing exposure control, stability and manufacturability. A platform description without drug-specific performance is less likely to support a premium transaction.

How does iloperidone compare with competing atypical antipsychotics?

Drug	Common dosage form	Key formulation or commercial issue
Iloperidone	Immediate-release tablet	Food requirement and seven-day titration
Risperidone	Tablet, ODT, liquid, long-acting injectable	Broad dosage-form and generic competition
Paliperidone	Extended-release tablet and long-acting injectables	Established depot franchise
Aripiprazole	Tablet, ODT, oral solution and long-acting injectables	Strong adherence-oriented product range
Lurasidone	Immediate-release tablet	Food requirement, generally at least 350 calories
Asenapine	Sublingual tablet and transdermal system	Nonstandard administration and delivery differentiation
Quetiapine	Immediate-release and extended-release tablets	Broad generic and modified-release competition

Iloperidone has less dosage-form breadth than aripiprazole, risperidone or paliperidone. Its food requirement resembles lurasidone’s commercial challenge. A new iloperidone product would need to improve administration convenience or exposure consistency to compete effectively.

What generic entry risks exist for iloperidone?

Generic entry risk is highest for a conventional immediate-release tablet that matches the reference product’s strengths and food instructions. Price erosion, payer substitution and pharmacy-level switching can rapidly reduce branded revenue after market entry.

Risk is lower for a differentiated formulation if it has:

• A separate patent estate.
• A clinically meaningful label distinction.
• A 505(b)(2) regulatory position.
• Limited substitutability under state pharmacy law.
• Specialty distribution or controlled initiation protocols.
• Evidence of improved adherence or reduced food-effect variability.

A generic manufacturer can also design around formulation claims by changing excipient ratios, manufacturing steps, coating composition or particle engineering, provided the product remains bioequivalent and does not infringe valid claims.

What licensing deals and commercial partnerships are relevant?

Iloperidone originated with Novartis and was later commercialized by Vanda Pharmaceuticals. The principal strategic value today is likely to come from product lifecycle partnerships rather than acquisition of basic iloperidone rights.

Potential transaction structures include:

• An excipient supplier licensing a food-effect mitigation platform to a 505(b)(2) sponsor.
• A specialty pharmaceutical company partnering with a sterile injectable manufacturer.
• A generic company licensing an ODT or titration-pack technology.
• A contract development and manufacturing organization supplying spray-dried dispersion or depot capabilities.
• A regional license for a differentiated formulation outside the United States.

Revenue exposure should be modeled by product type. A conventional generic typically has high volume but low margin. A patented ODT, food-independent tablet or long-acting injectable has lower development probability but greater pricing protection.

Key Takeaways

• Iloperidone’s main formulation weakness is the requirement to administer it with a meal of at least 350 calories.
• Food-effect mitigation is the most commercially relevant oral excipient opportunity.
• An ODT, titration kit or low-dose multiparticulate product could improve initiation and adherence.
• A long-acting injectable offers the largest differentiation opportunity but carries the highest clinical, manufacturing and regulatory risk.
• Core molecule protection is no longer the primary barrier; method-of-use and formulation patents determine remaining strategic value.
• The Vanda-Teva litigation shows that iloperidone commercial risk includes pharmacogenomic method patents, not only formulation patents.
• Routine excipient substitution has limited patent value unless it produces a measurable pharmacokinetic, stability or administration benefit.
• A new product should be evaluated under ANDA and 505(b)(2) strategies before formulation investment is committed.

FAQs About Iloperidone Excipient and Commercial Strategy

Can iloperidone be formulated as an orally disintegrating tablet?

Yes. An ODT is technically feasible, but the formulation must preserve dose uniformity, mask taste, control moisture uptake and demonstrate bioequivalence or otherwise support a revised pharmacokinetic profile.

Would a food-independent iloperidone formulation require new clinical studies?

Likely. A sponsor would need comparative fed and fasted pharmacokinetic studies and may require additional clinical evidence if the formulation changes exposure, labeling or the approved administration conditions.

Is lactose-free iloperidone a meaningful commercial opportunity?

It may address patients with lactose intolerance or excipient preferences, but lactose removal alone is unlikely to create strong market exclusivity. The commercial case would be stronger when combined with an ODT, food-effect improvement or other clinically relevant advantage.

Can an iloperidone long-acting injectable rely on the Fanapt tablet approval?

A sponsor may seek reliance on existing safety and efficacy information under a 505(b)(2) strategy, but the injectable route, depot technology and prolonged exposure profile would likely require additional studies.

Are iloperidone excipient patents likely to block generic tablets?

Only if valid, enforceable claims cover the generic product or its manufacturing process. Generic applicants can often design around narrow excipient claims, while method-of-use patents may be addressed through Paragraph IV certifications or labeling carve-outs.

References

1. U.S. Food and Drug Administration. (2024). Fanapt (iloperidone) tablets: U.S. prescribing information.
2. United States Court of Appeals for the Federal Circuit. (2023). Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., litigation concerning iloperidone CYP2D6-guided treatment claims.
3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.